aTyr Pharma is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Our lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause chronic inflammation and progressive fibrosis, or scarring, of the lungs. We are currently investigating efzofitimod in pulmonary sarcoidosis, a major form of ILD, and systemic sclerosis (SSc, or scleroderma)-related ILD. We recently reported topline results from the global Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis, and the Phase 2 EFZO-CONNECT™ study of efzofitimod in patients with SSc-ILD is ongoing. Efzofitimod has received U.S., E.U. and Japanese Orphan Drug designations and U.S. Fast Track designation for sarcoidosis. Additionally, efzofitimod has received U.S. and E.U. Orphan Drug designations and U.S. Fast Track designation for SSc. We also have a partnership with Kyorin Pharmaceutical, Co., Ltd., with a total deal value up to $175m, for the development and commercialization of efzofitimod for ILD in Japan. In addition to efzofitimod, we have a pipeline of therapeutic candidates derived from our tRNA synthetase platform targeting inflammation and fibrosis.